Navigation Links
Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
Date:9/17/2012

pies in the class of oncolytic immunotherapies," stated David H. Kirn, M.D., founder, chief medical officer and president of R&D of Jennerex.  "In the Phase 2 trial presented at ILCA, JX-594 demonstrated its ability to selectively target and destroy tumors following intravenous infusion. This finding confirms the ability of JX-594 to target both primary and metastatic, or distant, tumors which we believe is important in this HCC patient population and most cancers."

"We have treated more than 160 patients with JX-594 to date and are actively enrolling a multinational Phase 2b study in second line treatment of liver cancer patients, a Phase 2 all-IV trial in first line HCC patients, and a Phase 2 study in colorectal cancer.  The data presented today build on the growing body of promising clinical data showing that JX-594 has a direct anti-tumor effect and can stimulate an immune response killing cancer cells," stated Laurent Fischer, M.D., president and chief executive officer of Jennerex. "We are excited with the progress we are making in our JX-594 program and believe it has the potential to advance patient care across multiple types of cancer."

The abstract (#2012-1304) entitled "Phase 2 Trial Of JX-594, A Targeted Multi-Mechanistic Oncolytic Vaccinia Virus, Followed By Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)" was presented at the International Liver Cancer Association Annual Meeting in Berlin.

About this Trial:

Twenty five Asian patients with advanced HCC, 20 of whom were refractory to sorafenib, were treated with an initial intravenous dose of JX-594, and the majority of patients then received sequential intratumoral doses of JX-594 at week one and three. The majority of patients subsequently received treatment with sorafenib.

Following treatment with JX-594 alone at four weeks, 62 percent of patients had disease control as measured by modified RECIST (tumor burden measurement). 
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
2. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
3. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
4. Mettler Toledo Presents In-depth Guidance to Comply with New USP Chapters 41 and 1251 on Balances Used for Quantitative Analysis in the Pharma QC Lab
5. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
6. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
7. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
8. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
10. Grant & Eisenhofer Represents Key Whistleblower in Justice Dept.s $1.04 Billion Civil Settlement with GlaxoSmithKline
11. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... SOUTH EASTON, Mass. , Sept. 19, 2014 ... the "Company") today announced it has received and ... throughput Barozyme HT48 instruments and has begun to ... believes the first instrument will be ready for ... will be built and released at a rate ...
(Date:9/19/2014)... , September 19, 2014 ... IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt ... interaktive PDF, verfügbar unter pharmaserialisation.com , zeigt ... sie jeweils in Kraft treten. Für ... nicht länger um das "ob", sondern darum, "wann" ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. ... Inc. (PGDx), a provider of advanced cancer ... Medicines , a leader in discovering and developing ... today disclosed the first-ever comprehensive genomic study of ... deadly cancer of the female reproductive system, also ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... Choice and Access Now (PCAN) – a coalition ... nation and Texas, committed to preserving quality and ... for the passage of Senate Bill 7, which ... for Texans and their community pharmacies.  Among these ...
... Lilly and Company (NYSE: LLY ) announced ... the Clinical Endocrinology website, showed that Axiron® (testosterone) topical ... primary study objective to restore testosterone levels to the ... low testosterone. In addition, secondary outcomes showed that the ...
Cached Medicine Technology:Pharmacy Choice and Access Now Coalition Applauds Passage of Senate Bill 7 During Texas Legislature's Special Session 2Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 2Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 3Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 4Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 5Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 6
(Date:9/19/2014)... Alan Mozes HealthDay ... -- Cancer patients burdened by stress and family conflicts ... following their operation, a new study suggests. Investigators ... to have a nearly three times greater risk for ... quality of life. "We,ve long known that patient ...
(Date:9/19/2014)... a leading anti-ageing clinic has called its HGH Therapy ... has grown tremendously across USA in the last decade with ... It has far reaching benefits for ageing men and women ... and active lifestyle even beyond their middle age. , ... MetroMD said, “HGH or Human Growth hormones are the building ...
(Date:9/19/2014)... September 19, 2014 In partnership with Raw ... an active part of the project’s social media efforts. StudioPMG ... aims to re-define the perception of beauty as it applies ... as an idea by Shelly Baer and Vanessa Silberman, who ... as sexy and beautiful. Ginny Dixon, Wendy Crawford, Susan Solman ...
(Date:9/19/2014)... Recent two-generation approaches to reducing poverty that help ... from researchers, advocates, and foundations. By combining education ... move to jobs that offer a path out ... for children, these programs aim to improve the ... a new report from the National Center for ...
(Date:9/19/2014)... NY (PRWEB) September 20, 2014 As summer ... Krishnan DMD in Queens, NY now reminds area patients about ... than 80% of our population affected by gum disease, there ... longer.” , For over 20 years Dr. Krishnan has treated ... Hills office location. “Most patients that come in due to ...
Breaking Medicine News(10 mins):Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3
... , , , GLENVIEW, Ill., ... palliative medicine has launched a new Web site -- www.PalliativeDoctors.org ... and how it can help patients with serious illnesses, and their ... and Palliative Medicine (AAHPM) created www.PalliativeDoctors.org to meet a ...
... , , NORRISTOWN, Pa., Aug. 24 ... drugs for clinical research and clinical trials, has expanded ... new capability provides their clients with an efficient solution ... in clinical trials. Distribution Management Services is an ...
... , , , HACKENSACK, ... of The Prostate Net announced the organization,s latest major initiative ... symposium targeting patients, caregivers and medical professionals will take place ... Center for University Life in New York City. Joined ...
... , WASHINGTON, Aug. 24 Secretary of Veterans Affairs ... taking steps to assist Veterans seeking compensation for Post-Traumatic Stress Disorder ... are being addressed vigorously and comprehensively by this administration as we ... Secretary Shinseki. , , The VA is publishing ...
... , , ATLANTA, Aug. 24 ... by the American Diabetes Association (ADA), kicks off in Atlanta on ... F earless A frican-Americans C onnected and E ... also supported by Aetna, educates and empowers African-Americans living with diabetes ...
... EMERYVILLE, Calif., Aug. 24 Nov ... ), a clinical stage company developing non-antibiotic anti-infective compounds for the ... fungal infections, announced today the company has received acceptance to deliver ... Diseases Society of America October 29 - November 1, 2009 in ...
Cached Medicine News:Health News:www.PalliativeDoctors.org: Organization Sheds Light on Hospice and Palliative Care 2Health News:Prostate Net Announces: Major Medical Education Initiative for Patients, Caregivers and Healthcare Professionals 2Health News:Prostate Net Announces: Major Medical Education Initiative for Patients, Caregivers and Healthcare Professionals 3Health News:Secretary Shinseki Moves to Simplify PTSD Compensation Rules 2Health News:Grammy(R)-Nominated R&B Sensation Angie Stone Teams up With the American Diabetes Association to Encourage African-Americans to be Victorious in the Face of Diabetes 2Health News:Grammy(R)-Nominated R&B Sensation Angie Stone Teams up With the American Diabetes Association to Encourage African-Americans to be Victorious in the Face of Diabetes 3Health News:Grammy(R)-Nominated R&B Sensation Angie Stone Teams up With the American Diabetes Association to Encourage African-Americans to be Victorious in the Face of Diabetes 4Health News:NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting 2Health News:NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting 3
... Wolf offers protection in ... shielding values with lightweight ... optical quality. Lenses provide ... and are anti-reflection coated ...
... coat apron, weight is distributed uniformly ... comfortable wear without fatigue. Made to ... front closing special procedure apron comes ... that make it a cinch to ...
The O.R. Special Protective Apron is now available with an attached Thyroid Collar. The Thyroid Collar is held on with velcro so it adjusts to fully protect the neck. This Apron with Collar is availa...
The major innovation in posterior stabilized (PS) knee design. Improve patellofemoral kinematics. Reduce wear rate potential. Increase resistance to posterior tibial dislocation. Achieve at least 120...
Medicine Products: